Bristol-Myers Squibb Total Cost of Revenue decreased by 16.5% to $3.42B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.8%, from $3.03B to $3.42B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 8.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.45B | $2.29B | $2.36B | $2.47B | $2.72B | $2.35B | $2.59B | $2.57B | $2.88B | $2.51B | $2.75B | $2.93B | $3.27B | $2.96B | $4.81B | $3.03B | $3.37B | $3.44B | $4.10B | $3.42B |
| QoQ Change | — | -6.6% | +2.8% | +4.9% | +10.1% | -13.5% | +10.2% | -1.0% | +12.1% | -12.9% | +9.5% | +6.8% | +11.4% | -9.5% | +62.7% | -37.0% | +11.2% | +1.9% | +19.3% | -16.5% |
| YoY Change | — | — | — | — | +10.9% | +2.7% | +10.1% | +3.8% | +5.7% | +6.5% | +5.9% | +14.3% | +13.6% | +18.0% | +75.3% | +3.4% | +3.2% | +16.2% | -14.9% | +12.8% |